Cingulate Inc.

Public companies file this within four business days when something important happens that investors should know about before the next quarterly report.

Cingulate Inc. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. 1 Cingulate Receives Complete Response Letter from FDA for CTx-1301 No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company is Well Capitalized with Nearly $30 Million Cash on Hand KANSAS CITY, Kan. (NASDAQ: CING), a bi…